

25 November 2024

**IXICO plc
("IXICO" or the "Company")**

Notice of Results and Investor Presentation

IXICO PLC (AIM: IXI), the global medical imaging analysis company delivering insights in neuroscience, confirms that it will issue its Full Year Results for the year to 30 September 2024 on Wednesday 4 December 2024.

Bram Goorden (CEO) and Grant Nash (CFO) will provide a live presentation to all existing and potential shareholders relating to their Full Year Results and IXICO's expansion and growth strategy via:

The Vox platform on 4 December 2024 at 4.30pm GMT

Questions can be submitted pre-event by sending them to community@voxmarkets.co.uk up until 9:00am on the day before the meeting. There will also be an opportunity to ask questions during the presentation.

Investors can sign up here: <https://streamyard.com/watch/tuGDjEfcP5K4>.

The Investor Meet Company platform on 5 December 2024 at 4:30pm GMT.

Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9:00am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet **IXICO PLC** via:

<https://www.investormeetcompany.com/ixico-plc/register-investor>

Investors who already follow IXICO PLC on the Investor Meet Company platform will automatically be invited.

For further information please contact:

IXICO plc

Bram Goorden, Chief Executive Officer
Grant Nash, Chief Financial Officer

+44 (0)20 3763 7499

Cavendish Capital Markets Limited (Nominated adviser and sole broker)

Giles Balleny / Dan Hodgkinson (Corporate Finance)
Nigel Birks (Life Sciences Specialist Sales)
Harriet Ward (Corporate Broking)
Michael F Johnson / Tamar Cranford-Smith (Sales)

+44 (0)20 7220 0500

About IXICO | Advanced Analytics | Intelligent Insights.

IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis.

IXICO has developed and deployed breakthrough data analytics, at scale, through its remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients.

More information is available on www.IXICO.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this

communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NORQKQBBCBDDPDB